Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

To the Editor: Dialogue on the design, conduct, analysis, and reporting of comparative effectiveness research is important for formulating valid treatment guidance and ensuring effective and efficient health care resource utilization. The analysis by Barnett et al assessed the cost-effectiveness of long-acting injectable (LAI) risperidone versus physician’s choice of oral antipsychotics in Veterans Health Administration patients with unstable schizophrenia or schizoaffective disorder. The study on which this analysis was based (Rosenheck et al) was partly funded by our company. We fully support research characterizing our products’ efficacy, safety, appropriate use, and cost-effectiveness.